title: CA 549 and SP2 in postoperative breast cancer patients. Comparison with CA 15.3, CEA and TPA.
abstract: The levels of CA 549 and SP2 were measured in 430 subjects: 100 healthy blood donors, 130 patients with benign diseases and 200 postoperative breast cancer patients. In the latter group, the serum levels of CA 15.3, CEA and TPA were also measured. The Kolmogorov-Smirnov, Mann Whitney and McNemar tests were used for statistical analysis. The upper normal limits were established on the basis of the values obtained in the healthy blood donors group, the benign diseases group and R.O.C. analysis of the breast cancer group. They were: CA 549 = 13 U/ml, SP2 = 14 U/ml, CA 15.3 = 35 U/ml, CEA = 5 ng/ml and TPA = 110 U/ml. The sensitivity, specificity and accuracy in the breast cancer group were, respectively: CA 549 = 78.1%, 97.1% and 88%; SP2 = 21.9%, 90.4% and 57.5%; CEA = 66.7%, 95.2% and 81.5%; CA 15.3% = 80.2%, 98.1% and 89.5%, and TPA = 73.9%, 78.8% and 76.5%. Statistical analysis showed significant differences only between CA 15.3, the marker which gave the best results, and SP2 (p < 0.001). There was no significant differences with the association of two or three tumor markers.
authors.affiliation: Nuclear Medicine Service, Hospital Reina Sofía, Córdoba, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Torres
authors.forename: C
authors.initials: C
authors.lastname: Pacheco
authors.forename: A
authors.initials: A
authors.lastname: Valverde
authors.forename: A C
authors.initials: AC
authors.lastname: Rebollo
authors.forename: A
authors.initials: A
authors.lastname: Moral
authors.forename: J A
authors.initials: JA
authors.lastname: Vallejo
authors.forename: A
authors.initials: A
authors.lastname: Mateo
mesh_terms: D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001941:Breast Diseases / Q000097:blood; D001943:Breast Neoplasms / Q000097:blood* / Q000601:surgery; D002272:Carcinoembryonic Antigen / Q000032:analysis; D004066:Digestive System Diseases / Q000097:blood; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood; D007676:Kidney Failure, Chronic / Q000097:blood; D018396:Mucin-1 / Q000032:analysis; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000097:blood*; D009419:Nerve Tissue Proteins / Q000097:blood*; D009687:Nuclear Proteins; D010455:Peptides / Q000032:analysis; D011184:Postoperative Period; D012372:ROC Curve; D012261:Ribonucleoproteins; D012680:Sensitivity and Specificity; D000072668:Splicing Factor U2AF; D019396:Tissue Polypeptide Antigen
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; C072700:CA549 glycoprotein, human; D002272:Carcinoembryonic Antigen; D006023:Glycoproteins; D018396:Mucin-1; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D009687:Nuclear Proteins; D010455:Peptides; D012261:Ribonucleoproteins; D000072668:Splicing Factor U2AF; D019396:Tissue Polypeptide Antigen; C000607495:Zrsr1 protein, mouse